hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Along with oxidane, water is one of the two official names for the chemical compound H2O; it is also the liquid phase of H2O. The other two common states of matter of water are the solid phase, which is ice, and the gaseous phase, water vapor or steam. The addition or removal of heat can cause phase transitions: freezing (water to ice), melting (ice to water), vaporization (water to vapor), condensation (vapor to water), sublimation (ice to vapor) and deposition (vapor to ice).
Similarly, the risk of exercise-induced hyperglycemia can be managed by avoiding exercise when insulin levels are very low, when blood sugar is extremely high (above 350 mg/dL or 19.4 mmol/L), or when one feels unwell. When focusing on the type of exercise, the first two studies explicitly focus on the role of exercise in managing diabetes, with the first study exploring the benefits of HIIT for psychological and physical health in T1DM and the second focusing on the effectiveness of exercise in T2DM. The third study, however, discusses the implications of diabetes misdiagnosis, which indirectly relates to exercise by stressing the importance of managing diabetes properly before engaging in physical activity. For the impacts that exercise has, the first and second studies highlight exercise as a beneficial tool for managing diabetes, but they present different outcomes. In T2DM, exercise is shown to be a powerful tool for improving glycemic control and reducing cardiovascular risk. In T1DM, while exercise can improve lipid profiles and other aspects of health, it doesn't necessarily lead to better blood sugar control, and there are additional barriers, such as fear of hypoglycemia. The first study, however, finds that HIIT can still be effective in improving psychological well-being and exercise adherence for T1DM, showing that exercise has a broader benefit beyond just metabolic control. All three studies provide insight into the barriers to exercise in diabetes.
The passing of time may mean political situations change and a burial can take place in different circumstances. Roger Casement was executed at Pentonville Prison in London on 3 August 1916 and buried in the prison grounds but his body was exhumed and given a state funeral in Dublin on 1 March 1965. Deceased individuals who were either not identified or misidentified at the time of burial may be reburied if survivors so wish. For example, when the remains of MIA soldiers are discovered, or the case of Nicholas II of Russia and his family, who were exhumed from unmarked graves near Yekaterinburg to be reinterred in the Peter and Paul Fortress in St. Petersburg. Cemeteries sometimes have a limited number of plots in which to bury the dead. Once all plots are full, older remains may be moved to an ossuary to accommodate more bodies, in accordance with burial contracts, religious and local burial laws. In Hong Kong where real estate is at a premium, burials in government-run cemeteries are disinterred after six years under exhumation order. Remains are either collected privately for cremation or reburied in an urn or niche. Unclaimed burials are exhumed and cremated by the government. Permanent burial in privately run cemeteries is allowed. In Singapore, cremation is preferred by most Singaporeans because burials in Singapore is limited to 15 years. After 15 years, Singaporean graves will be exhumed and the remains will either be cremated or re-interred.
Sources: en.wikipedia.org
A cilium (fine hair) which projects above the surface and acts as a trigger. Spirocysts do not have cilia. A tough capsule, the cnida, which houses the thread, its payload and a mixture of chemicals that may include venom or adhesives or both. ("cnida" is derived from the Greek word κνίδη, which means "nettle") A tube-like extension of the wall of the cnida that points into the cnida, like the finger of a rubber glove pushed inwards. When a cnidocyte fires, the finger pops out. If the cell is a venomous nematocyte, the "finger"'s tip reveals a set of barbs that anchor it in the prey. The thread, which is an extension of the "finger" and coils round it until the cnidocyte fires. The thread is usually hollow and delivers chemicals from the cnida to the target. An operculum (lid) over the end of the cnida. The lid may be a single hinged flap or three flaps arranged like slices of pie. The cell body, which produces all the other parts. It is difficult to study the firing mechanisms of cnidocytes as these structures are small but very complex. At least four hypotheses have been proposed:
=== Ravenholm === In 2007 or 2008, Valve gave the Junction Point project to Arkane Studios in Lyon, France. They developed it into a game with the working title Ravenholm, referred to by some sources as Episode Four. Players controlled Adrian Shephard from Opposing Force, working alongside Father Grigori, who had taken refuge in an abandoned psychiatric hospital. Grigori was experimenting with the effects of headcrab venom on himself, and would mutate through the story. The player would use the magnet gun and traps created by Grigori against enemies. Arkane also implemented a nail gun that could create paths to conduct electricity and set traps. Valve gave Arkane freedom to develop Ravenholm, as they had with Gearbox and Opposing Force, providing feedback and technical support. With approximately one year left of development, Valve canceled the project. The Arkane founder, Raphaël Colantonio, believed that Valve decided it would be too expensive. Laidlaw said Valve felt the premise was creatively constrained, and that Arkane, like Valve with Episode Three, had struggled to discover fun new game mechanics with the Half-Life 2 tools. Ravenholm was first shown publicly in a 2020 Noclip documentary. Noclip released an hour of gameplay footage in 2022.
The D/H fractionations in clays such as kaolinite, illite, smectite are in most cases consistent when no significant external forces are applied under constant temperature and pressure. The following is an empirically determined equation for estimating the D/H fractionation factor: 1000 In αkaolinite-water = −2.2 × 106 × T−2 − 7.7. The δDs vs. ‰SMOW for hydrogen minerals found in mantle, metamorphic rock, shales, marine clays, marine carbonates and sedimentary rocks are shown in the table.
Sources: en.wikipedia.org
=== Usage === To obtain the greatest benefits from its use as a sudorific, it was recommended that copious drafts of some warm and harmless drink be ingested after the use of the powder. It was an ingredient in John Wyeth & Brother, Inc.'s La Grippe (flu) pills, circa 1906.
In men, blockade of the AR by bicalutamide in the pituitary gland and hypothalamus prevents the negative feedback of androgens on the hypothalamic–pituitary–gonadal (HPG) axis, resulting in an increase in luteinizing hormone (LH) secretion and levels. Follicle-stimulating hormone (FSH) levels, in contrast, remain essentially unchanged. The increase in LH levels leads to an elevation in androgen and estrogen levels. At a dosage of 150 mg/day, bicalutamide has been found to increase testosterone levels by about 1.5- to 2-fold (59–97% increase) and estradiol levels by about 1.5- to 2.5-fold (65–146% increase). However, there is variability in these increases, and in one clinical trial, the highest testosterone concentration that occurred with 50 mg/day bicalutamide monotherapy was 2,306 ng/dL, which was five times the normal average level of testosterone in men. Levels of DHT are also increased to a lesser extent (by 24–30%), and concentrations of sex hormone-binding globulin (SHBG) and prolactin increase as well (by 8–42% and 40–65%, respectively) secondary to the increase in estradiol levels. The estradiol concentrations produced in men by bicalutamide monotherapy are said to approximate the low-normal estradiol levels of a premenopausal woman, while testosterone levels generally remain in the high end of the normal male range and rarely exceed it.
== Strong acids and bases == An acid is classified as "strong" when the concentration of its undissociated species is too low to be measured. Any aqueous acid with a pKa value of less than 0 is almost completely deprotonated and is considered a strong acid. All such acids transfer their protons to water and form the solvent cation species (H3O+ in aqueous solution) so that they all have essentially the same acidity, a phenomenon known as solvent leveling. They are said to be fully dissociated in aqueous solution because the amount of undissociated acid, in equilibrium with the dissociation products, is below the detection limit. Likewise, any aqueous base with an association constant pKb less than about 0, corresponding to pKa greater than about 14, is leveled to OH− and is considered a strong base. Nitric acid, with a pK value of around −1.7, behaves as a strong acid in aqueous solutions with a pH greater than 1. At lower pH values it behaves as a weak acid. pKa values for strong acids have been estimated by theoretical means. For example, the pKa value of aqueous HCl has been estimated as −9.3.
=== 1960s–1990s === In 1960, Rogers asked to buy into Toddle House, and was subsequently refused. Afterwards, he moved back to Atlanta and rejoined Waffle House, now a chain of three restaurants, to run restaurant operations. Shortly after Rogers returned full-time, Forkner followed suit and left Ben S. Forkner Realty. After opening a fourth restaurant in 1960, the company began franchising its restaurants and slowly grew to 27 stores by the late 1960s, before growth accelerated.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.